1454 - Diagnostic testing for ROS proto-oncogene 1 (ROS1) rearrangements in non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment

Page last updated: 07 November 2018

Application Detail



Description of Medical Service

Testing of tumour material in patients with non-small cell lung cancer (NSCLC) to detect chromosomal rearrangements in the ROS1 gene to determine eligibility for treatment with Xalkori (crizotinib) through the PBS.
PBS subsidy will also be sought for Xalkori (crizotinib) for the treatment of patients with ROS1-rearranged NSCLC.

Description of Medical Condition

Patients with non-squamous non-small cell lung cancer (NSCLC).

Reason for Application

New MBS item

Medical Service Type

Co-dependent technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 314 KB)
Application Form (Word 559 KB)

PICO Confirmation

PICO Confirmation (PDF 330 KB)
PICO Confirmation (Word 204 KB)

Assessment Report


Public Summary Document

Public Summary Document (PDF 320 KB)
Public Summary Document (Word 120 KB)

Meetings for this Application


8 December 2016


5 October 2017


23 November 2017
26-27 July 2018